Vicplas International Ltd, an investment holding company, researches, designs, develops, manufactures, and assembles medical devices in Singapore, Malaysia, and China.
Excellent balance sheet and fair value.
Share Price & News
How has Vicplas International's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
SG Medical Equipment
1 Year Return
SG Medical Equipment
Return vs Industry: 569 exceeded the SG Medical Equipment industry which returned -20.3% over the past year.
Return vs Market: 569 underperformed the SG Market which returned 0.6% over the past year.
Price Volatility Vs. Market
How volatile is Vicplas International's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StInvestors Who Bought Vicplas International (SGX:569) Shares Three Years Ago Are Now Down 40%
1 month ago | Simply Wall StShould Vicplas International Ltd’s (SGX:569) Weak Investment Returns Worry You?
1 month ago | Simply Wall StDo Directors Own Vicplas International Ltd (SGX:569) Shares?
Is Vicplas International undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Undervalued: 569 (SGD0.09) is trading above our estimate of fair value (SGD0.06)
Significantly Undervalued: 569 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 569 is good value based on its PE Ratio (10.4x) compared to the Medical Equipment industry average (23.3x).
PE vs Market: 569 is good value based on its PE Ratio (10.4x) compared to the SG market (13.5x).
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate 569's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 569 is good value based on its PB Ratio (0.7x) compared to the SG Medical Equipment industry average (0.7x).
How is Vicplas International forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 569's forecast earnings growth (10.8% per year) is above the savings rate (2.3%).
Earnings vs Market: 569's earnings (10.8% per year) are forecast to grow faster than the SG market (5.6% per year).
High Growth Earnings: 569's earnings are forecast to grow, but not significantly.
Revenue vs Market: Insufficient data to determine if 569's revenue is forecast to grow faster than the SG market.
High Growth Revenue: Insufficient data to determine if 569's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: Insufficient data to determine if 569's Return on Equity is forecast to be high in 3 years time
How has Vicplas International performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: 569 has become profitable over the past 5 years, growing earnings by 12.7% per year.
Accelerating Growth: 569's earnings growth over the past year (43.6%) exceeds its 5-year average (12.7% per year).
Earnings vs Industry: 569 earnings growth over the past year (43.6%) exceeded the Medical Equipment industry 17.9%.
Return on Equity
High ROE: 569's Return on Equity (6.9%) is considered low.
Return on Assets
ROA vs Industry: 569's Return on Assets is below or equal to the Medical Equipment industry average last year.
Return on Capital Employed
ROCE Improving: 569's Return on Capital Employed has declined over the past 3 years.
How is Vicplas International's financial position?
Financial Position Analysis
Short Term Liabilities: 569's short term assets (SGD45.9M) exceeds its short term liabilities (SGD20.2M)
Long Term Liabilities: 569's short term assets (45.9M) exceeds its long term liabilities (1.6M)
Debt to Equity History and Analysis
Debt Level: 569's debt to equity ratio (14.3%) is considered satisfactory
Reducing Debt: 569's debt to equity ratio has increased from 2.1% to 14.3% over the past 5 years.
Debt Coverage: 569's debt is well covered by operating cash flow (24%).
Interest Coverage: 569's interest payments on its debt are well covered by EBIT (12.6x coverage).
Inventory Level: 569 has a high level of physical assets or inventory.
Debt Coverage by Assets: 569's debt is covered by short term assets (assets are 5.325870x debt).
What is Vicplas International's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Purchase Vicplas International before the 'Buy Limit' to receive their next dividend payment.
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: 569's dividend (5.75%) is higher than the bottom 25% of dividend payers in the SG market (2.55%).
High Dividend: 569's dividend (5.75%) is in the top 25% of dividend payers in the SG market (5.71%)
Stable Dividend: 569 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 569's dividend payments have increased, but the company has only paid a dividend for 9 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (59.6%), 569's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
What is the CEO of Vicplas International's salary, the management and board of directors tenure and is there insider trading?
Average management tenure
Liang Cheng (64yo)
Mr. Liang Cheng has been Group Chief Executive Officer of Vicplas International Ltd since November 1, 2018 having served as its Acting Chief Executive Officer since October 31, 2014 and also is responsibl ...
Management Age and Tenure
Experienced Management: 569's management team is considered experienced (4.5 years average tenure).
Board Age and Tenure
Experienced Board: 569's board of directors are considered experienced (6 years average tenure).
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Liang Cheng (64yo)
Group Chief Executive Officer
- Tenure: 5yrs
Ying Hui Gan (40yo)
Chief Financial Officer
- Tenure: 3.5yrs
- Tenure: 7.6yrs
Hsheng Cheng (42yo)
Group Operations Director
- Tenure: 4.5yrs
Chin Toon (41yo)
- Tenure: 4.4yrs
Walter Tarca (62yo)
President of Medical Devices Segment
- Tenure: 3.8yrs
Robert Gaines-Coopers (82yo)
- Tenure: 4.3yrs
Cher Yan Ng (60yo)
Non-Executive Independent Director
- Tenure: 9.4yrs
Jane Rose Philomene Gaines-Cooper (59yo)
- Tenure: 2.9yrs
Wico Yeo (52yo)
Non-Executive Independent Chairman
- Tenure: 10.1yrs
Chris Lee (57yo)
- Tenure: 6yrs
Vicplas International Ltd's company bio, employee growth, exchange listings and data sources
- Name: Vicplas International Ltd
- Ticker: 569
- Exchange: SGX
- Founded: 1993
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: S$44.128m
- Shares outstanding: 507.22m
- Website: https://www.vicplas.com
- Vicplas International Ltd
- 35 Joo Koon Circle
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|569||SGX (Singapore Exchange)||Yes||Ordinary Shares||SG||SGD||Apr 1999|
Vicplas International Ltd, an investment holding company, researches, designs, develops, manufactures, and assembles medical devices in Singapore, Malaysia, and China. The company operates through two segm ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/10/19 12:37|
|End of Day Share Price||2019/10/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.